Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von fchar99 

Insmed Inc. diskutieren

Insmed Inc.

WKN: A1JJA3 / Symbol: INSM / Name: Insmed / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

23,60 €
-0,84 %

Einschätzung Buy
Rendite (%) 11,22 %
Kursziel 26,16
Veränderung
Endet am 06.09.17

fchar99 stimmt der Buy-Einschätzung von melinda zu

fchar99 stimmt am 05.09.2017 der Buy-Einschätzung von melinda mit dem Kursziel 16.0$ zu.
Überschrift: Santé | Biotechnologie | Etats-Unis

Einschätzung Buy
Rendite (%) 11,22 %
Kursziel 26,16
Veränderung
Endet am 06.09.17

(Zielkurs erreicht)

Buy Insmed Inc.

Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 16,00 %
Kursziel 47,17
Veränderung
Endet am 04.08.24

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 16,00 %
Kursziel 37,17
Veränderung
Endet am 04.08.24

Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $41.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,69 %
Kursziel 48,49
Veränderung
Endet am 05.09.24

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Guggenheim from $50.00 to $52.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,69 %
Kursziel 48,47
Veränderung
Endet am 06.09.24

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,28 %
Kursziel 43,04
Veränderung
Endet am 19.09.24

Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $46.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,36 %
Kursziel 32,94
Veränderung
Endet am 20.11.24

Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $36.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,53 %
Kursziel 51,16
Veränderung
Endet am 08.12.24

Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $55.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,38 %
Kursziel 38,99
Veränderung
Endet am 15.02.25

Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,45 %
Kursziel 42,39
Veränderung
Endet am 27.02.25

Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $46.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,45 %
Kursziel 49,73
Veränderung
Endet am 27.02.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Guggenheim from $52.00 to $54.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -6,45 %
Kursziel 51,22
Veränderung
Endet am 01.04.25

Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $55.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,43 %
Kursziel 37,34
Veränderung
Endet am 11.04.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Barclays PLC from $37.00 to $40.00. They now have an "overweight" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,52 %
Kursziel 44,97
Veränderung
Endet am 23.04.25

Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $48.00 price target on the stock.
Ratings data for INSM provided by MarketBeat